Yinan Ren

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 5 篇 · 总被引 90 次 · h-index 4

代表论文

• Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis (2022 · Frontiers in Pharmacology · 被引 27)
• Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China (2022 · Frontiers in Public Health · 被引 26)
• Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China (2022 · Frontiers in Public Health · 被引 24)
• Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis (2021 · Frontiers in Public Health · 被引 12)
• 2021TiP INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC) (2024 · Annals of Oncology · 被引 1)